• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exscientia Ltd ADR (NQ: EXAI )

    4.963 +0.103 (+2.13%)
    Streaming Delayed Price Updated: 2:40 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Exscientia Ltd ADR

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
    From Exscientia plc
    Via Business Wire
    Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
    From Exscientia plc
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
    The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
    Via Talk Markets
    Topics Economy
    Exposures Economy
    Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Exscientia plc
    Via Business Wire
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
    Via Talk Markets
    The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
    Merging with a former rival will bolster its capabilities. 
    Via The Motley Fool
    EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
    EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Exscientia Business Update for Second Quarter and First Half 2024
    From Exscientia plc
    Via Business Wire
    AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
    The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
    Via Talk Markets
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    From FN Media Group LLC
    Via GlobeNewswire
    Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
    The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
    Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
    Operational complementarities expected to yield annual synergies of approximately $100 million 
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
    Via Talk Markets
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
    Via Talk Markets
    Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
    From Exscientia plc
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
    From Exscientia plc
    Via Business Wire
    3 Small-Cap Stocks With Explosive 2X Growth Potential
    Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
    Via Talk Markets
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.